Studying the immune system in pleural mesothelioma tumors
Studies how the immune system interacts with pleural mesothelioma tumors in adults.
Plain-language title generated from the registry record
Registry title: Multidimensional Omics Analysis in Malignant Pleural Mesothelioma
Key facts
- Where
- Catania, Naples, Reggio Emilia, and Roma, ItalySee the 4 sites
Where in Italy
- Azienda Ospedaliera Universitaria Policlinico Rodolico San Marco di CataniaCatania, ItalyTaking people
- Azienda Ospedaliera Universitaria Luigi Vanvitelli, NapoliNaples, ItalyTaking people
- Azienda USL IRCCS di Reggio EmiliaReggio Emilia, ItalyTaking people
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRoma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda USL Reggio Emilia - IRCCS
- Trial code
- NCT07561190
- Record updated
- 1 May 2026
- Original description
Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited. The lack of prognostic biomarkers further complicates the decision-making. Recently, the introduction of immune checkpoint inhibitors (ICIs) has marked a shift but has failed to produce significant benefits for a large proportion of patients. Maximizing the efficiency of ICIs and developing new protocols to improve drug efficacy is the best possible strategy for improving the life expectancy and quality of life of patients with MPM. This study aims to characterize the organization of the immune system infiltrating mesothelioma and the dynamics of its interaction with the tumor. The rationale is that deciphering this complexity will help improve our understanding of the mechanisms underlying this disease and provide a new tool to optimize the use of ICIs in these patients.Read full original descriptionShow less
Multidimensional Omics and Functional Approaches to Improve Immunotherapy Efficacy in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited. The lack of prognostic biomarkers further complicates the decision-making. Recently, the introduction of immune checkpoint inhibitors (ICIs) has marked a shift but has failed to produce significant benefits for a large proportion of patients. Maximizing the efficiency of ICIs and developing new protocols to improve drug efficacy is the best possible strategy for improving the life expectancy and quality of life of patients with MPM. This study aims to characterize the organization of the immune system infiltrating mesothelioma and the dynamics of its interaction with the tumor. The rationale is that deciphering this complexity will help improve our understanding of the mechanisms underlying this disease and provide a new tool to optimize the use of ICIs in these patients.
Inclusion: Participant is willing and able to give informed consent for participation in the study; Aged > 18 years; Patients with histologically confirmed diagnosis of MPM; Availability of biological material; Clinical indicatio of eligibility for HITOCH protocol (only for C3 cohort).
Exclusion: Active current infection; Autoimmune disease; Women in childbearing age not able to exclude pregnancy.